SI-BONE, Inc. Announces 2024 Annual Meeting of Stockholders
Ticker: SIBN · Form: DEF 14A · Filed: 2024-04-29T00:00:00.000Z
Sentiment: bullish
Topics: SI-BONE, Annual Meeting, Proxy Statement, Financial Results, Medical Devices
Related Tickers: SIBN
TL;DR
<b>SI-BONE invites stockholders to its 2024 Annual Meeting on June 25, 2024, highlighting significant 2023 financial and operational achievements.</b>
AI Summary
SI-BONE, Inc. (SIBN) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. SI-BONE achieved worldwide revenue of $138.9 million in 2023, a 31% increase over 2022. Over 1,600 physicians performed an iFuse procedure in 2023, a 23% increase from 2022. Gross margins reached 79% for the full year 2023. Net loss improved by 30% and Adjusted EBITDA by 48% in 2023. The company ended 2023 with $166 million in cash and equivalents, including $84 million from a May 2023 follow-on offering.
Why It Matters
For investors and stakeholders tracking SI-BONE, Inc., this filing contains several important signals. The meeting provides a platform for shareholders to understand the company's strategic direction and performance, with a focus on growth and innovation in the sacroiliac joint treatment market. Key financial metrics like revenue growth, improved net loss, and strong cash position demonstrate the company's progress and financial health, which are crucial for investor confidence and future investment.
Risk Assessment
Risk Level: low — SI-BONE, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate negative financial or operational news, indicating a stable outlook.
Analyst Insight
Stockholders should review the proxy materials to understand executive compensation, board nominations, and the company's strategic priorities for the upcoming year.
Financial Highlights
- revenue
- 138.9
- gross Margin
- 79%
- cash Position
- 166
- revenue Growth
- 31%
Key Numbers
- 138.9 — 2023 Revenue (Worldwide revenue in millions USD)
- 31% — Revenue Growth (Year-over-year increase for 2023)
- 95,000 — Procedures Performed (Total procedures since inception)
- 1,600 — Physicians Performing iFuse (Number of physicians in 2023)
- 23% — Physician Increase (Increase in physicians performing iFuse in 2023)
- 79% — Gross Margin (Full year 2023)
- 30% — Net Loss Improvement (Percentage improvement in 2023)
- 166 — Cash and Equivalents (End of 2023 balance in millions USD)
Key Players & Entities
- SI-BONE, Inc. (company) — Registrant name
- June 25, 2024 (date) — Annual Meeting date
- $138.9 million (dollar_amount) — 2023 worldwide revenue
- 31% (percentage) — Revenue increase over 2022
- 79% (percentage) — 2023 gross margins
- $166 million (dollar_amount) — Cash and equivalents at end of 2023
FAQ
When did SI-BONE, Inc. file this DEF 14A?
SI-BONE, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 29, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by SI-BONE, Inc. (SIBN).
Where can I read the original DEF 14A filing from SI-BONE, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by SI-BONE, Inc..
What are the key takeaways from SI-BONE, Inc.'s DEF 14A?
SI-BONE, Inc. filed this DEF 14A on April 29, 2024. Key takeaways: SI-BONE achieved worldwide revenue of $138.9 million in 2023, a 31% increase over 2022.. Over 1,600 physicians performed an iFuse procedure in 2023, a 23% increase from 2022.. Gross margins reached 79% for the full year 2023..
Is SI-BONE, Inc. a risky investment based on this filing?
Based on this DEF 14A, SI-BONE, Inc. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting, with no immediate negative financial or operational news, indicating a stable outlook.
What should investors do after reading SI-BONE, Inc.'s DEF 14A?
Stockholders should review the proxy materials to understand executive compensation, board nominations, and the company's strategic priorities for the upcoming year. The overall sentiment from this filing is bullish.
Key Dates
- 2024-06-25: Annual Meeting of Stockholders — Key date for shareholder voting and company updates.
- 2024-04-29: Filing Date — Date the Definitive Proxy Statement was filed.
- 2023-12-31: Fiscal Year End — Period for which financial highlights are reported.
Filing Stats: 4,858 words · 19 min read · ~16 pages · Grade level 12.7 · Accepted 2024-04-29 16:04:25
Key Financial Figures
- $138.9 million — llowing Achieved worldwide revenue of $138.9 million for the full year 2023, representing an
- $166 million — ed 2023 with a solid balance sheet with $166 million in cash and equivalents, including $84
- $84 million — lion in cash and equivalents, including $84 million in net proceeds from our follow-on offe
Filing Documents
- sibn2024proxystatementfinal.htm (DEF 14A) — 774KB
- capvsnetloss.jpg (GRAPHIC) — 335KB
- capvstsr.jpg (GRAPHIC) — 331KB
- ceotrgtpaymix2023.jpg (GRAPHIC) — 120KB
- neosaverage.jpg (GRAPHIC) — 119KB
- proxycard_pagex2.jpg (GRAPHIC) — 206KB
- proxypage1.jpg (GRAPHIC) — 90KB
- si-bonecdapsuchart0224.jpg (GRAPHIC) — 103KB
- 0001459839-24-000031.txt ( ) — 2570KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 17 MANAGEMENT 18
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 19
Executive Compensation Narrative
Executive Compensation Narrative 19 Overview 19 Compensation Philosophy and Guiding Principles 22 Compensation-Setting Process 28 Compensation Elements 30 SI-BONE, Inc. Severance Benefit Plan 35 Employment Arrangements 35 Other Compensation Policies 36 Tax and Accounting Considerations 36 Summary Compensation Table 37 Outstanding Equity Awards at December 31, 2023 34 Pension Benefits 34 Nonqualified Deferred Compensation 35 Securities Authorized for Issuance under Equity Compensation Plans 35 Compensation of Non-Employee Board Members 36 Non-Employee Director Compensation Policy 37 Pay vs. Performance 38 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 42 Related Person Transactions Policy and Procedures 42 Certain Related Person Transactions 42 INDEMNIFICATION AGREEMENTS 42 HOUSEHOLDING OF PROXY MATERIALS 43 OTHER MATTERS 43 QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Why did I receive a notice regarding the availability of proxy materials on the internet Pursuant to rules adopted by the Securities and Exchange Commission (the "SEC"), we have elected to provide access to our proxy materials over the internet. Accordingly, we have sent you a Notice of Internet Availability of Proxy Materials (the "Notice") because our board of directors (the or our "Board" or "Board of Directors") is soliciting your proxy to vote at the 2024 Annual Meeting of Stockholders, including at any adjournments or postponements of the meeting. All stockholders will have the ability to access the proxy materials on the website referred to in the Notice or request to receive a printed set of the proxy materials. Instructions on how to access the proxy materials over the internet or to request a printed copy may be found in the Notice. We intend to first mail this Notice and make this proxy statement and the form of proxy available to stockholders on or about April 29, 2024. How do I attend the Ann